I wouldn't be saying that just yet. I had a look on every one of them (Jens Eckstein, Lesley Russell, Kim Drapkin, Jakob Dupont) on linkedin. Their past experiences and job titles do not suggest that their roles would be those that are normally in direct discussion with Prof. YF or others about Clinical Trials.
And if all of them did buy, wouldn't that signify a loose lip from PH's and LC's end? I got a feeling these 2 just want another bag to fill (probably one last big one as these 2 took the lot) which exerts real confidence as they are IMO the ones that have the first-hand knowledge of what is going on with the trial results?
Just my opinion.
I wouldn't be saying that just yet. I had a look on every one of...
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $364.4M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 5.2¢ | 4.9¢ | $531.4K | 10.66M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 3429444 | 4.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.0¢ | 149299 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |